Diagnosis and therapy of chronic pulmonary hypertension;Diagnostik und therapie der chronischen pulmonalen hypertonie

Pneumologie

Volumn 60, Issue 12, 2006, Pages 749-771

  Olschewski, Horst ^a,b   Hoeper, M M ^b   Borst, M M ^b   Ewert, R ^b   Grunig E ^b   Kleber, F X ^b   Kopp, B ^b   Opitz, C ^b   Reichenberger, F ^b   Schmeisser, A ^b   Schranz, D ^b   Schulze Neick, I ^b   Wilkens, H ^b   Winkler, J ^b   Worth, H ^b  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

^b Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMBRISENTAN; AMINOREX; AMLODIPINE; ANGIOTENSIN ANTAGONIST; ANTIBIOTIC AGENT; BERAPROST; BOSENTAN; CALCIUM ANTAGONIST; CLOPIDOGREL; CONTRACEPTIVE AGENT; DEXFENFLURAMINE; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENFLURAMINE; ILOPROST; NIFEDIPINE; NITRATE; PROCYCLIN; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; UNIPROST;

ANTICOAGULATION; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COR PULMONALE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EISENMENGER COMPLEX; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROTHERAPY; LUNG TRANSPLANTATION; OXYGEN THERAPY; PHYSICAL ACTIVITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL BEHAVIOR;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; RANDOMIZED CONTROLLED TRIALS; TERMINOLOGY;

EID: 33846213203     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-954981     Document Type: Review

References (46)

1. Galie N, Torbicki A, Barst R et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25 (24): 2243-2278
2. Gurtner HP, Walser P, Fässler B. Normal values for pulmonary hemodynamics at rest and during exercise in man. Progr Resp Res 1975; 9: 295-315
3. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S): 40S-47S
4. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40 (4): 780-788
5. Wensel R, Opitz CF, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106 (3): 319-324
6. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115 (5): 343-349
7. Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161 (2 Pt 1): 487-492
8. Deng Z, Morse JH, Stager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67 (3): 737-744
9. Grunig E, Koehler R, Miltenberger-Miltenyi G et al. Primary Pulmonary Hypertension in Children May Have a Different Genetic Background than in Adults. Pediatr Res, 2004
10. Krowka MJ, Mandell MS, Ramsay MA et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10 (2): 174-182
11. Weitzenblum E, Hirth C, Ducolone A et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36 (10): 752-758
12. Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350 (22): 2257-2264
13. Grunig E, Janssen B, Mereles D et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000; 102 (10): 1145-1150
14. Raymond RJ, Hinderliter AL, Willis PW et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39 (7): 1214-1219
15. Yeo TC, Dujardin KS, Tei C et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81 (9): 1157-1161
16. Simonneau G, Barst RJ, Galie N et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (6): 800-804
17. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (5): 322-329
18. Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39 (9): 1496-1502
19. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12): 896-903
20. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327 (2): 76-81
21. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111 (23): 3105-3111
22. Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S): 5S-12S
23. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99 (9): 1197-1208
24. Meyer FJ, Ewert R, Hoeper M et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax 2002; 57 (6): 473-476
25. Mereles D, Ehlken N, Kreuscher S et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114 (14): 1482-1489
26. Magnussen H, Goeckenjan G, Kohler D et al. [Guidelines to long-term oxygen therapy]. Pneumologie 2001; 55 (10): 454-464
27. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334 (5): 296-302
28. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132 (6): 425-434
29. Barst RJ, McGoon M, McLaughlin V et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41 (12): 2119-2125
30. Galie N, Beghetti M, Gatzonlis N et al. Breathe-5: Bosentan improves hemodynamics and exercise capacity in the first randomized placebo-controlled trial in Eisenmenger physiology. Chest 2005; 128 (4): 496S
31. Barst RJ, Langleben D, Badesch D et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47 (10): 2049-2056
32. Galie N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46 (3): 529-535
33. Sastry BK, Narasimhan C, Ready NK et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43 (7): 1149-1153
34. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20): 2148-2157
35. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42 (1): 158-164
36. Hoeper MM, Faulenbach C, Golpon H et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24 (6): 1007-1010
37. Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360 (9337): 895-900
38. Ghofrani HA, Schermuly RT, Rose F et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167 (8): 1139-1141
39. Hoeper MM, Markevych I, Spiekerkoetter E et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. European Respiratory Journal 2005; 26 (5): 858-863
40. Reichenberger F, Pepke-Zaba J, McNeil K et al. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 2003; 58 (9): 797-800
41. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99 (14): 1858-1865
42. Califf RM, Adams KF, McKenna WJ et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134 (1): 44-54
43. Olschewski H, Ghofrani HA, Walmrath D et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (2): 600-607
44. Klepetko W, Mayer E, Sandoval J et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S): 73S-80S
45. Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132 (6): 435-443
46. Hoeper MM, Galie N, Murali S et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165 (3): 341-344